乳がん治療の世界市場

【英語タイトル】Breast Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

Transparency Market Researchが出版した調査資料(TMR602445)・商品コード:TMR602445
・発行会社(調査会社):Transparency Market Research
・発行日:2015年11月
・ページ数:88
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD4,795 ⇒換算¥517,860見積依頼/購入/質問フォーム
Multi UserUSD7,795 ⇒換算¥841,860見積依頼/購入/質問フォーム
Corporate LicenseUSD10,795 ⇒換算¥1,165,860見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、乳がん治療の世界市場について調査・分析し、乳がん治療の世界市場概要、市場動向、市場規模、主要地域別分析、関連企業情報などをお届けいたします。
【レポートの概要】

This report on the breast cancer therapeutics market studies the current as well as future prospects of the market globally. The stakeholders of this report include pharmaceutical companies and intermediaries engaged in the new drug discovery, pipeline development of various breast cancer therapeutics as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the overall information and data analysis of the global breast cancer therapeutics market with respect to the leading market segments in terms of geography.

The global breast cancer therapeutics market has been studied based on major drug class segments, and their regional as well as national markets. Based on drug class, the global market has been categorized into five major segments: HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormone receptors. The market for these segments and sub-segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn and compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all segments, considering 2014 as the base year.

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the breast cancer therapeutics market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is illustrated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market.

Geographically, the breast cancer therapeutics market has been segmented into five regions: North America (the U.S. and Canada), Europe (the U.K., Germany, and Rest of Europe), Asia Pacific (Japan, South Korea, and Rest of APAC), Latin America (Brazil and Rest of Latin America), and Middle East & Africa (MEA). Market revenue in terms of US$ Mn and CAGR % from 2015 to 2023 are provided for all the regions and countries, considering 2014 as the base year.

The recommendations section included in the report would assist existing market players in expanding their market shares and new pharmaceutical companies in establishing their presence in the global breast cancer market. The report also profiles leading and emerging new players in the breast cancer therapeutics market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Puma Biotechnology, Sanofi S.A., and Teva Pharmaceutical Industries Ltd.

【レポートの目次】

1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
2 Executive Summary
2.1 Global Breast Cancer Therapeutics: Market Snapshot
2.2 Global Breast Cancer Therapeutics Market Share, by Geography, 2014 & 2023(Value %)
2.3 Global Breast Cancer Therapeutics Market, by Drug Class, 2014 & 2023 (Value %)
3 Global Breast Cancer Therapeutics Market – Market Overview
3.1 Market Definition and Overview
3.2 Epidemiology & High Risk Groups
3.3 Diagnosis and Types of Breast Cancer
3.4 Other Breast Cancer Therapies
3.5 Market Dynamics
3.5.1 Drivers
3.5.1.1 Higher Incidence Rate
3.5.1.2 Demographic Transition
3.5.1.3 Rising Prevalence Of Obesity
3.5.1.4 Diagnostic Screening Programs
3.5.1.5 Increase in Private Health Insurance Plans:
3.5.2 Restraints
3.5.2.1 Generic Drugs: Substitute Branded Drugs
3.5.2.2 Intense Competition: Fall in Prices
3.5.2.3 Access barriers due to high drug costs
3.5.2.4 Absence of Social Health Insurance
3.5.2.5 Serious Side Effects of Breast Cancer Therapeutics
3.5.2.6 Countries Lacking Women Empowerment
3.5.3.7 Newer medication options
3.5.3 Opportunities
3.5.3.1 Potential Growth of Domestic Pharmaceutical Companies
3.5.3.2 Combination Drug Therapy
3.5.3.3 Technological Advancements and Robust Trends of Drug Approval
3.5.3.4 New Companion Diagnostics Models
3.5.3.5 Drug Therapy for Triple Negative (TNBC)
3.5.3.6 Approval for Multiple Indications (positive & negative types) HER2 breast cancer
3.7 Market Attractiveness Analysis– Breast Cancer Therapeutics Market, by Geography (2014) (%)
3.8 Competitive Landscape – Breast Cancer Therapeutics Market, by Key Players, 2014 (%)
4 Market Segmentation – By Drug Class
4.1 Overview
4.2 Global HER2 Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.2.1 Herceptin (Trastuzumab)
4.2.2 Tykerb (Lapatinib)
4.2.3 Perjeta (Pertuzumab)
4.2.4 Kadcyla (Ado-trastuzumab emtansine)
4.3 Global Mitotic Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.3.1 Halaven (Eribulin)
4.3.2 Taxotere (Docetaxel)
4.3.3 Ixempra (Ixabepilone)
4.4 Global Anti-metabolites Market Revenue, 2015–2023 (US$ Mn)
4.4.1 Gemzar (Gemcitabine)
4.5 Global Aromatase Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.5.1 Femara (Leterozole)
4.5.2 Aromasin (Exemestane)
4.5.3 Arimidex (Anastrozole)
4.5.4 Ibrance (Palbociclib)
4.5.5 Afinitor (Everolimus)
4.6 Global Hormone Receptor Market Revenue, 2015–2023 (US$ Mn)
4.6.1 Zoladex
4.6.2 Faslodex
4.6.3 Fareston
5 Market Segmentation – By Geography
5.1 Introduction
5.2 Global Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.3 North America Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.3.1 U.S.
5.3.2 Canada
5.4 Europe Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.4.1 Germany
5.4.3 U.K.
5.4.4 Rest of Europe
5.5 Asia Pacific Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.5.1 Japan
5.5.2 South Korea
5.5.3 Rest of Asia Pacific
5.6 Rest of the World
5.6.1 Latin America
5.6.1.1 Brazil
5.6.1.2 Rest of Latin America
5.6.2 Middle East and Africa
6 Recommendations
7 Company Profiles
7.1 AstraZeneca plc
7.2 Eisai Co., Ltd.
7.3 Eli Lilly and Company
7.4 F. Hoffmann-La Roche Ltd.
7.5 GlaxoSmithKline plc
7.6 Novartis International AG
7.7 Pfizer, Inc.
7.8 Puma Biotechnology, Inc.
7.9 Sanofi S.A.
7.10 Teva Pharmaceutical Industries Ltd.



★調査レポート[乳がん治療の世界市場] (コード:TMR602445)販売に関する免責事項を必ずご確認ください。
★調査レポート[乳がん治療の世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆